FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to a method for modifying a target locus of interest, including the delivery to the specified locus of a composition, not found in nature or constructed, containing effector CRISPR-Cas protein of type VI, class 2, containing 2 HEPN domains, and one or more components, which are nucleic acids. A composition, not found in nature or constructed, for modifying RNA of interest, as well as a delivery system containing it for modifying the target locus of interest, and a vector system for modifying the target locus of interest, including one or more vectors, are also disclosed. The invention also relates to a cell for modifying RNA of interest, as well as to a cell line containing it.
EFFECT: invention is effective for modification of a target locus of interest.
60 cl, 146 dwg, 12 tbl, 9 ex
Title | Year | Author | Number |
---|---|---|---|
NEW ENZYMES AND CRISPR SYSTEMS | 2016 |
|
RU2777988C2 |
NOVEL ENZYMES AND CRISPR SYSTEMS | 2016 |
|
RU2737537C2 |
TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
UNNATURAL PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS (PRRSV) AND METHODS OF APPLICATION | 2015 |
|
RU2687150C2 |
COMPOSITIONS AND METHODS FOR DEGRADATION OF IMPROPERLY PACKAGED PROTEINS | 2016 |
|
RU2761564C2 |
MATERIALS AND METHODS USED FOR TREATMENT OF RESPIRATORY DISEASES IN DOGS | 2020 |
|
RU2811752C2 |
COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | 2017 |
|
RU2795467C2 |
TREATING CANCER USING A CHIMERIC ANTIGENIC CLL-1 RECEPTOR | 2015 |
|
RU2741120C2 |
AAV VECTORS AIMED AT THE CENTRAL NERVOUS SYSTEM | 2015 |
|
RU2727015C2 |
BIOLOGICAL MATERIALS FOR MODULATING IMMUNE RESPONSES | 2017 |
|
RU2770060C2 |
Authors
Dates
2022-05-12—Published
2016-06-17—Filed